Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurod... AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Mehr anzeigen
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high...
AC Immune to Present at the Jefferies 2024 London Healthcare Conference Lausanne, Switzerland, November 13, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company...
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease (PD) on track to report interim safety and...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.11 | -3.28358208955 | 3.35 | 3.88 | 3.11 | 228137 | 3.41529178 | CS |
| 4 | 0.16 | 5.19480519481 | 3.08 | 3.88 | 2.8 | 126017 | 3.23442273 | CS |
| 12 | 0.03 | 0.934579439252 | 3.21 | 3.98 | 2.8 | 100841 | 3.31507448 | CS |
| 26 | 0.05 | 1.56739811912 | 3.19 | 4.95 | 2.8 | 178121 | 3.80358267 | CS |
| 52 | 0.1 | 3.1847133758 | 3.14 | 5.14 | 2.25 | 318600 | 3.45863065 | CS |
| 156 | -2.33 | -41.8312387792 | 5.57 | 5.62 | 1.68 | 255057 | 3.35570357 | CS |
| 260 | -4.65 | -58.9353612167 | 7.89 | 14.89 | 1.68 | 431654 | 6.1048598 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
